1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,020 | 1,040 | 29.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ABBISKO-B (02256): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| Fr | ABBISKO-B (02256): PROXY FORM FOR EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| Fr | ABBISKO-B (02256): PROPOSED CHANGE OF COMPANY NAME AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| Di | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| Mo | ABBISKO-B (02256): PROPOSED CHANGE OF COMPANY NAME | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| Mo | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 19.08. | ABBISKO-B ABSK211 Receives NMPA Approval for IND Application | 1 | AASTOCKS | ||
| 19.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES IND CLEARANCE FROM THE NMPA FOR ORAL SMALL MOLECULE PAN-KRAS INHIBITOR ABSK211 | 1 | HKEx | ||
| 03.08. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE PAN-KRAS INHIBITOR ABSK211 | 1 | HKEx | ||
| 08.07. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 02.07. | Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance | 6 | Benzinga.com | ||
| 02.07. | AstraZeneca, Abbisko partner on lung cancer combination therapy trial | 2 | Seeking Alpha | ||
| 02.07. | Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO for NSCLC | 212 | PR Newswire | SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered... ► Artikel lesen | |
| 02.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS AND ASTRAZENECA ENTER A STRATEGIC COLLABORATION TO CONDUCT THE CLINICAL TRIAL OF LUMIPODLIN ... | 1 | HKEx | ||
| 29.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 26.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS REPORTS PHASE II DATA OF ABSK061 IN COMBINATION WITH ABSK043 IN FGFR2-POSITIVE ADVANCED ... | 1 | HKEx | ||
| 25.06. | Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration | 4 | Forbes | ||
| 24.06. | Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact | 2 | Benzinga.com | ||
| 24.06. | Abbisko Therapeutics, Lilly Expand R&D Alliance | 5 | Contract Pharma |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Merck, Vidac Pharma, Moderna - Neue Krebswaffen elektrisieren die Börse | Ein Durchbruch in der Krebsforschung versetzte die Börse in der vergangenen Woche in Euphorie. Eine personalisierte mRNA-Therapie hat erstmals in einer großen Phase-3-Studie entscheidende Ziele erreicht... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,66 % bei einem Aktienkurs von 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.